OPKO Health, Inc. (NYSE: OPK )
announced that its investee, Neovasc, has received conditional
Investigational Device Exemption (IDE) approval from the U.S. Food and
Drug Administration (FDA) to initiate the U.S. arm of its TIARA-I Early
Feasibility Trial for the Company’s Tiara™ transcatheter mitral valve.
for Neovasc, an OPKO Investee, Receives FDA Conditional Approval to Initiate TIARA-I Trial in U.S.: A Multinational, Multicenter Early Feasibility Trial of the TiaraTM Transcatheter Mitral Valve investment picks